|
|
Article: Clinic Roundup.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Aegis Therapeutics LLC, of San Diego, completed its first clinical study, a 10-patient, three-way crossover trial, designed to confirm the effectiveness of Intravail absorption enhancement agents in increasing intranasal bioavailability of peptide and protein drugs. The study revealed an average systemic bioavailability of about 35 percent for the Intravail formulation of a marketed drug, compared to an average of 7 percent for the identical commercial formulation without Intravail. Aegis' product offers high bioavailability performance via the intranasal and other mucosal membrane administration routes.
o Amgen Inc., of Thousand Oaks, Calif., started the ...
Related newspaper, magazine, and journal articles:
|
|
Article: Meetings calendar.(Calendar)
Renal & Urology News;
November 1, 2006 ;
700+ words
... ... site: www.isn-online.org May 20-23, Renal Association Spring Meeting 2007, Brighton, U.K. Contact ... renal.org June 21-24, XLIV European Renal Association European Dialysis and Transplant Association Congress 2007 ...
|
|